Compare IDR & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDR | KMDA |
|---|---|---|
| Founded | 1996 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.0M | 460.3M |
| IPO Year | 2000 | 2013 |
| Metric | IDR | KMDA |
|---|---|---|
| Price | $31.18 | $7.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 205.7K | 74.9K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | ★ 70.15 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $42,406,253.00 | N/A |
| Revenue This Year | $25.52 | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | $50.70 | ★ $24.59 |
| Revenue Growth | ★ 64.59 | N/A |
| 52 Week Low | $22.31 | $6.50 |
| 52 Week High | $54.70 | $9.35 |
| Indicator | IDR | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 63.79 |
| Support Level | $27.46 | $7.66 |
| Resistance Level | $41.05 | $8.55 |
| Average True Range (ATR) | 1.82 | 0.20 |
| MACD | 0.23 | 0.07 |
| Stochastic Oscillator | 41.09 | 87.68 |
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.